Clinical Utility of Noninvasive Fetal Trisomy (NIFTY) Test--early Experience

Overview

Journal J Matern Fetal Neonatal Med

Publisher Informa Healthcare

Specialty Gynecology & Obstetrics

Date 2012 Apr 5

PMID 22471583

Citations 13

Authors

Tze Kin Lau

Mei Ki Chan

Pui Shan Salome Lo

Hon Yee Connie Chan

Wai Sze Kim Chan

Tik Yee Koo

Hoi Yan Joyce Ng

Ritsuko K Pooh

Affiliations

Soon will be listed here.

Abstract

Objective: To report the initial experience of noninvasive prenatal diagnosis of fetal Down syndrome (The NIFTY test) in a clinical setting.

Methods: The NIFTY test was offered as a screening test for fetal Down syndrome to pregnant women with a singleton pregnancy at 12 weeks of gestation or beyond. A satisfaction questionnaire was sent to the first 400 patients.

Results: During a 6-month period, 567 NIFTY tests were performed. Over 90% of those studied were ethnic Chinese, and the mean age of the women studied was 36 years. The test was performed at 12-13 weeks of gestation in 49.21%. The median reporting time was 9 days. The test was positive for trisomy 21 in eight cases, and for trisomy 18 in 1 case; all were confirmed by fetal karyotyping. There was no false-positive result. Of the questionnaires, 182 completed responses were received. Over 95% had complete or almost complete resolution of anxiety. Except for one, all were satisfied with the NIFTY test, and all indicated that they would recommend the test to their friends.

Conclusion: The NIFTY test was a highly specific test. Unnecessary invasive tests and associated fetal losses could be avoided in almost all women who have a normal fetus.

Citing Articles

NIPT Integration as a Patient-Paid Prenatal Screening Option-Observations and Challenges from a Bulgarian Genetic Counseling Center.

Yahya D, Hachmeriyan M, Stoyanova M, Levkova M Med Sci (Basel). 2025; 13(1.

PMID: 39846698 PMC: 11755488. DOI: 10.3390/medsci13010003.

Approach and Management of Pregnancies with Risk Identified by Non-Invasive Prenatal Testing.

Gug M, Ratiu A, Andreescu N, Farcas S, Laitin S, Gug C J Pers Med. 2024; 14(4).

PMID: 38672993 PMC: 11050912. DOI: 10.3390/jpm14040366.

Whole genome non-invasive prenatal testing in prenatal screening algorithm: clinical experience from 12,700 pregnancies.

Baranova E, Sagaydak O, Galaktionova A, Kuznetsova E, Kaplanova M, Makarova M BMC Pregnancy Childbirth. 2022; 22(1):633.

PMID: 35945516 PMC: 9364619. DOI: 10.1186/s12884-022-04966-8.

Effective Identification of Maternal Malignancies in Pregnancies Undergoing Noninvasive Prenatal Testing.

Li J, Ju J, Zhao Q, Liu W, Yuan Y, Liu Q Front Genet. 2022; 13:802865.

PMID: 35265103 PMC: 8900746. DOI: 10.3389/fgene.2022.802865.

Systematic evaluation of NIPT aneuploidy detection software tools with clinically validated NIPT samples.

Paluoja P, Teder H, ArdeshirDavani A, Bayindir B, Vermeesch J, Salumets A PLoS Comput Biol. 2021; 17(12):e1009684.

PMID: 34928946 PMC: 8722721. DOI: 10.1371/journal.pcbi.1009684.

References

Benn P, Borrell A, Cuckle H, Dugoff L, Gross S, Johnson J . Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn. 2012; 32(1):1-2. DOI: 10.1002/pd.2919. View

Lau T, Chen F, Pan X, Pooh R, Jiang F, Li Y . Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing. J Matern Fetal Neonatal Med. 2011; 25(8):1370-4. DOI: 10.3109/14767058.2011.635730. View

Leung T, Vogel I, Lau T, Chong W, Hyett J, Petersen O . Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype. Ultrasound Obstet Gynecol. 2011; 38(3):314-9. DOI: 10.1002/uog.8988. View

Chen E, Chiu R, Sun H, Akolekar R, Chan K, Leung T . Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One. 2011; 6(7):e21791. PMC: 3130771. DOI: 10.1371/journal.pone.0021791. View

Ehrich M, Deciu C, Zwiefelhofer T, Tynan J, Cagasan L, Tim R . Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011; 204(3):205.e1-11. DOI: 10.1016/j.ajog.2010.12.060. View

Palomaki G, Deciu C, Kloza E, Lambert-Messerlian G, Haddow J, Neveux L . DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med. 2012; 14(3):296-305. PMC: 3938175. DOI: 10.1038/gim.2011.73. View

Leung T, Chan L, Law L, Sahota D, Fung T, Leung T . First trimester combined screening for Trisomy 21 in Hong Kong: outcome of the first 10,000 cases. J Matern Fetal Neonatal Med. 2008; 22(4):300-4. DOI: 10.1080/14767050802430842. View

Susanne G, Sissel S, Ulla W, Charlotta G, Sonja O . Pregnant women's responses to information about an increased risk of carrying a baby with Down syndrome. Birth. 2006; 33(1):64-73. DOI: 10.1111/j.0730-7659.2006.00075.x. View

Nicolaides K . Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011; 31(1):7-15. DOI: 10.1002/pd.2637. View

10.

Tischler R, Hudgins L, Blumenfeld Y, Greely H, Ormond K . Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn. 2011; 31(13):1292-9. PMC: 3225485. DOI: 10.1002/pd.2888. View

11.

Lo Y, Corbetta N, Chamberlain P, Rai V, Sargent I, Redman C . Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350(9076):485-7. DOI: 10.1016/S0140-6736(97)02174-0. View

12.

Sehnert A, Rhees B, Comstock D, de Feo E, Heilek G, Burke J . Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem. 2011; 57(7):1042-9. DOI: 10.1373/clinchem.2011.165910. View